Oral Administration of Cannabis and Delta-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review


Por: Poyatos, L, Perez-Acevedo, AP, Papaseit, E, Perez-Mana, C, Martin, S, Hladun, O, Siles, A, Torrens, M, Busardo, FP and Farre, M

Publicada: 1 jun 2020 Ahead of Print: 23 jun 2020
Resumen:
Background and objective: Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration.Materials and Methods: A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans.Results: The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration.Conclusions: Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.

Direcciones
Poyatos, L: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
Perez-Acevedo, AP: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
Papaseit, E: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
Perez-Mana, C: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
Martin, S: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain
Hladun, O: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
Siles, A: Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Hosp Badalona Germans Trias & Pujol, Pharm Dept, Badalona 08916, Spain
Torrens, M: Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain; Parc Salut Mar, Drug Addict Program, Inst Neuropsiquiatria, Barcelona 08003, Spain; Inst Hosp del Mar Recerca Med PSMAR IMIM, Barcelona 08003, Spain
Busardo, FP: Univ Politecn Marche, Dept Excellence Biomed Sci & Publ Hlth, I-60121 Ancona, Italy
Farre, M: Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain; Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain; Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain; Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
ISSN: 16489144





MEDICINA-LITHUANIA
Editorial
Kauno Medicinos Universitetas, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Lituania
Tipo de documento: Review
Volumen: 56 Número: 6
Páginas:
WOS Id: 000551182800061
ID de PubMed: 32585912
imagen Green Published, gold

MÉTRICAS